About: Evanthia Galanis

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Evanthia Galanis Goto Sponge NotDistinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

researcher (ORCID 0000-0001-8014-786X)

Attributes	Values
rdf:type	Item
description	ikertzailea (eu) 연구원 (ko) araştırmacı (tr) wetenschapper (nl) дослідниця (uk) 研究者 (zh) researcher (ORCID 0000-0001-8014-786X) (en)
rdfs:label	Evanthia Galanis (en) Evanthia Galanis (nl) Evanthia Galanis (ast) Ευανθία Γαλάνη (el)
skos:prefLabel	Evanthia Galanis (en) Evanthia Galanis (nl) Evanthia Galanis (ast) Ευανθία Γαλάνη (el)
name	Evanthia Galanis (en) Evanthia Galanis (nl) Evanthia Galanis (ast) Ευανθία Γαλάνη (el)
instance of	wds:Q88613246-DC0FE50B-165A-4136-9E3A-3DD8D78C1AB5
instance of	Homo sapiens
award received	wds:Q88613246-3CB4D79D-7632-49EF-981E-D59AA22EA186
award received	honorary doctor of the University of Athens
native language	wds:Q88613246-BD1F6ACD-5A0D-4AF9-91BE-AE00ADCF005F
occupation	wds:Q88613246-05391C38-56FA-4EEE-B9EA-88F1487E6DC4 wds:Q88613246-76BEC18D-AE3D-4FC7-87C8-2138517576AE wds:Q88613246-CEB29F5D-2DE9-4A5C-B431-788BFA54BF37
employer	wds:Q88613246-4C1E0B35-F35A-4FBB-8C54-05FDA481E46B wds:Q88613246-78AF2D4C-9809-4720-B957-F3ACD15FA6EE
languages spoken, written or signed	wds:Q88613246-03969BCB-3E8F-4784-AF2A-CB41180E6CF0 wds:Q88613246-B8A3BBFE-7DD9-4F66-8118-4ECE40F90B4C
name in native language	wds:Q88613246-FCD3500E-4BBF-452C-BCEB-255ADDF74052
place of birth	wds:Q88613246-FBF9673A-CE5A-427B-AD7A-9C408C6644AF
sex or gender	wds:Q88613246-AA7ADBD0-F898-432F-811D-33767D88CF7D
country of citizenship	wds:Q88613246-2ADC354F-0A61-45F3-9D6B-0992D8B13826 wds:Q88613246-B40855A8-AF17-4AA6-879B-C800B151B59F
date of birth	wds:Q88613246-3303D066-8232-4419-8CA9-575A1D0FBEA4
educated at	wds:Q88613246-BB924406-2E0F-438A-AC6D-2A9B901788F2
native language	Greek
occupation	writer oncologist researcher
employer	Mayo Clinic National and Kapodistrian University of Athens
languages spoken, written or signed	Greek English
name in native language	Ευανθία Γαλάνη (el)
place of birth	Karditsa
sex or gender	female organism
country of citizenship	Groupement de recherche et d'études pour la civilisation européenne United States of America
date of birth	1965-01-01 00:00:00Z (xsd:dateTime)
educated at	National and Kapodistrian University of Athens
ORCID iD	wds:Q88613246-26AD5A76-188F-4448-B715-2AC06C0DB824
ORCID iD	https://orcid.org/0000-0001-8014-786X
ORCID iD	0000-0001-8014-786X
is owl:sameAs of	Evanthia Galanis
is about of	https://www.wikidata.org/wiki/Special:EntityData/Q88613246 https://el.wikipedia.org/wiki/%CE%95%CF%85%CE%B1%CE%BD%CE%B8%CE%AF%CE%B1_%CE%93%CE%B1%CE%BB%CE%AC%CE%BD%CE%B7
is author of	Patient tumor EGFR and PDGFRA gene amplifications retained in an invasive intracranial xenograft model of glioblastoma multiforme Neutralization capacity of measles virus H protein specific IgG determines the balance between antibody-enhanced infectivity and protection in microglial cells Phase II trial of intravenous administration of Reolysin(®) (Reovirus Serotype-3-dearing Strain) in patients with metastatic melanoma Consensus recommendations for a standardized Brain Tumor Imaging Protocol in clinical trials Validation of neuroradiologic response assessment in gliomas: measurement by RECIST, two-dimensional, computer-assisted tumor area, and computer-assisted tumor volume methods PTEN loss does not predict for response to RAD001 (Everolimus) in a glioblastoma orthotopic xenograft test panel Vorinostat in solid and hematologic malignancies North Central Cancer Treatment Group Phase I trial N057K of everolimus (RAD001) and temozolomide in combination with radiation therapy in patients with newly diagnosed glioblastoma multiforme Phase I trial of intraperitoneal administration of an oncolytic measles virus strain engineered to express carcinoembryonic antigen for recurrent ovarian cancer Intraperitoneal therapy of ovarian cancer using an engineered measles virus. Engineered measles virus as a novel oncolytic therapy against prostate cancer Pilocytic astrocytoma survival in adults: analysis of the Surveillance, Epidemiology, and End Results Program of the National Cancer Institute Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study Phase II trial of vorinostat in combination with bortezomib in recurrent glioblastoma: a north central cancer treatment group study Noninvasive imaging and radiovirotherapy of prostate cancer using an oncolytic measles virus expressing the sodium iodide symporter Mesenchymal stem cell carriers protect oncolytic measles viruses from antibody neutralization in an orthotopic ovarian cancer therapy model Epidermal growth factor receptor (EGFR)-retargeted measles virus strains effectively target EGFR- or EGFRvIII expressing gliomas A measles virus vaccine strain derivative as a novel oncolytic agent against breast cancer Identification of molecular characteristics correlated with glioblastoma sensitivity to EGFR kinase inhibition through use of an intracranial xenograft test panel Phase II trial of gemcitabine in advanced sarcomas Reovirus-associated reduction of microRNA-let-7d is related to the increased apoptotic death of cancer cells in clinical samples Phase II trial of two different irinotecan schedules with pharmacokinetic analysis in patients with recurrent glioma: North Central Cancer Treatment Group results Incorporation of prognostic and predictive factors into glioma clinical trials Dephosphorylation of HuR protein during alphavirus infection is associated with HuR relocalization to the cytoplasm Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. Phase II trial of vorinostat in recurrent glioblastoma multiforme: a north central cancer treatment group study Oncolytic measles virus strains in the treatment of gliomas Targeting Src family kinases inhibits bevacizumab-induced glioma cell invasion Clinical trial results with oncolytic virotherapy: a century of promise, a decade of progress Retargeted oncolytic measles strains entering via the EGFRvIII receptor maintain significant antitumor activity against gliomas with increased tumor specificity Clinical testing of engineered oncolytic measles virus strains in the treatment of cancer: an overview Targeting angiogenesis: progress with anti-VEGF treatment with large molecules A phase II trial of everolimus, temozolomide, and radiotherapy in patients with newly diagnosed glioblastoma: NCCTG N057K Interleukin-13 displaying retargeted oncolytic measles virus strains have significant activity against gliomas with improved specificity Phase II study of bevacizumab in combination with sorafenib in recurrent glioblastoma (N0776): a north central cancer treatment group trial Phase 2 trial design in neuro-oncology revisited: a report from the RANO group Optimizing patient derived mesenchymal stem cells as virus carriers for a phase I clinical trial in ovarian cancer Clinical trial end points for high-grade glioma: the evolving landscape. Toxicology study of repeat intracerebral administration of a measles virus derivative producing carcinoembryonic antigen in rhesus macaques in support of a phase I/II clinical trial for patients with recurrent gliomas Phase II Trial of Intravenous CI-1042 in Patients With Metastatic Colorectal Cancer

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 195 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software